Alzheimer Disease: Standard of Diagnosis, Treatment, Care, and Prevention.
PET
amyloid
biomarkers
dementia
prevention
treatment
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
01
10
2021
revised:
24
01
2022
pubmed:
12
2
2022
medline:
6
7
2022
entrez:
11
2
2022
Statut:
ppublish
Résumé
Alzheimer disease (AD) is the most frequent cause of dementia in people 60 y old or older. This white paper summarizes the current standards of AD diagnosis, treatment, care, and prevention. Cerebrospinal fluid and PET measures of cerebral amyloidosis and tauopathy allow the diagnosis of AD even before dementia (prodromal stage) and provide endpoints for treatments aimed at slowing the AD course. Licensed pharmacologic symptomatic drugs enhance cholinergic pathways and moderate excess of glutamatergic transmission to stabilize cognition. Disease-modifying experimental drugs moderate or remove brain amyloidosis, but so far with modest clinical effects. Nonpharmacologic interventions and a healthy lifestyle (diet, socioaffective inclusion, cognitive stimulation, physical exercise, and others) provide some beneficial effects. Prevention targets mainly modifiable dementia risk factors such as unhealthy lifestyle, cardiovascular-metabolic and sleep-wake cycle abnormalities, and mental disorders. A major challenge for the future is telemonitoring in the real world of these modifiable risk factors.
Identifiants
pubmed: 35145015
pii: jnumed.121.262239
doi: 10.2967/jnumed.121.262239
pmc: PMC9258577
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
981-985Informations de copyright
© 2022 by the Society of Nuclear Medicine and Molecular Imaging.
Références
Neurology. 2019 Oct 22;93(17):e1647-e1659
pubmed: 31371569
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Lancet. 2015 Jun 6;385(9984):2255-63
pubmed: 25771249
JAMA Neurol. 2019 Jul 1;76(7):791-799
pubmed: 31009028
J Neurol Neurosurg Psychiatry. 2011 Mar;82(3):240-6
pubmed: 20802215
Nat Commun. 2020 Apr 3;11(1):1683
pubmed: 32246036
NeuroRx. 2004 Apr;1(2):213-25
pubmed: 15717022
Lancet Neurol. 2014 Jun;13(6):614-29
pubmed: 24849862
Folia Neuropathol. 2014;52(3):211-25
pubmed: 25310732
JAMA Neurol. 2019 Sep 01;76(9):1060-1069
pubmed: 31233127
Lancet. 2016 Aug 20;388(10046):797-805
pubmed: 27474376
Front Neurosci. 2019 May 15;13:472
pubmed: 31156366
JAMA. 2015 May 19;313(19):1924-38
pubmed: 25988462
Alzheimers Dement. 2018 Sep;14(9):1216-1231
pubmed: 29936147
Neurology. 1989 Sep;39(9):1159-65
pubmed: 2771064
Neurobiol Aging. 2020 Jan;85:58-73
pubmed: 31739167
JAMA. 2020 Aug 25;324(8):772-781
pubmed: 32722745
J Alzheimers Dis. 2018;64(1):71-78
pubmed: 29865075
N Engl J Med. 2021 May 6;384(18):1691-1704
pubmed: 33720637
BMJ Open. 2015 Apr 02;5(4):e005247
pubmed: 25838501
Soc Psychiatry Psychiatr Epidemiol. 2018 Dec;53(12):1289-1301
pubmed: 30255384
Alzheimers Dement. 2020 Jul;16(7):1078-1094
pubmed: 32627328
Science. 1992 Apr 10;256(5054):184-5
pubmed: 1566067
J Alzheimers Dis. 2015;44(3):1015-21
pubmed: 25391382
Complement Ther Med. 2019 Dec;47:102199
pubmed: 31780033
J Clin Exp Neuropsychol. 1998 Jun;20(3):310-9
pubmed: 9845158
Lancet. 2020 Aug 8;396(10248):413-446
pubmed: 32738937
Alzheimers Res Ther. 2021 Apr 17;13(1):80
pubmed: 33865446
Alzheimer Dis Assoc Disord. 2018 Jan-Mar;32(1):10-17
pubmed: 29240561
J Alzheimers Dis. 2016 Nov 19;55(2):691-701
pubmed: 27716668
Nat Med. 2020 Mar;26(3):379-386
pubmed: 32123385
Alzheimer Dis Assoc Disord. 2018 Jan-Mar;32(1):28-34
pubmed: 29334498
Lancet Public Health. 2017 Mar;2(3):e149-e156
pubmed: 29253388
BMC Geriatr. 2019 Aug 1;19(1):203
pubmed: 31370792
Alzheimers Dement. 2011 May;7(3):280-92
pubmed: 21514248